
Why government red tape is draining your phone's battery potential
You're not alone if you're pining for longer battery life from your latest smartphone. Despite emerging technologies like silicon-carbon cells, we've seemingly hit a ceiling just above the 5,000 mAh mark — at least for phones sold in the US and Europe. Meanwhile, glance over at models in China or India, and you'll spot far larger batteries in otherwise identical handsets.
For example, the new Nothing Phone 3 packs a 5,150mAh battery globally, but bumps that up to 5,500mAh in India. The HONOR Magic 7 Pro goes from 5,270mAh in Europe to 5,850mAh in China, and the Xiaomi 15 Ultra stretches from 5,410mAh globally to a massive 6,000mAh in its domestic market. So what gives? Why can't we have these same huge battery capacities on the other side of the world too?
Wouldn't you know it? Regulation and red tape are to blame
Rita El Khoury / Android Authority
If you've ever attempted to ship a phone by post in Europe or the US (and probably many other countries too), you might have been interrogated by the postmaster about the size of the battery and whether it's sealed in the device. That's because many countries treat lithium-ion batteries as hazardous goods, with strict rules on how they're packaged and transported. The same rules apply — often even more stringently — to commercial shipments moving by air, road, rail, or sea.
Several major international regulations govern this. In Europe, there's the ADR (covering road transport), RID (rail), and IMDG (sea). For air shipments, carriers follow the International Air Transport Association's (IATA) Dangerous Goods Regulations (DGR) and the International Civil Aviation Organization (ICAO) rules. In the US, there's also the Code of Federal Regulations, 49 CFR § 173.185, which lays out similar requirements, and other nations sometimes have their own rule variations.
All of these regulations ultimately trace back to the UN's Model Regulations, which define lithium-ion batteries as either UN3480 (batteries shipped on their own) or UN3481 (batteries packed with or inside equipment). But the most important piece is UN Special Provision 188, which sets a threshold for what's considered a 'small' lithium-ion battery that can be shipped under simplified rules. That limit is 20Wh (watt-hours) per cell, and it's mirrored in the ADR, IMDG, IATA, and other international rules that govern global transportation networks. For context, there's also a 100Wh limit for a complete battery pack before stricter transport classifications kick in — but that's more relevant for laptops and power banks.
International transport rules cap single-cell li-ion capacity at 20Wh, roughly 5,300mAh.
A 20Wh cap might sound large, but it's tied to the battery's voltage. For a typical lithium-ion cell with a nominal voltage around 3.8 V, this works out to roughly 5,300mAh per cell — which is about where most modern smartphone batteries in Europe and the US max out. That's why you might notice slightly smaller battery capacities in these markets compared to some models sold in countries with fewer shipping constraints.
While these rules might be annoying from a consumer product perspective, they exist for a very good reason. Lithium-ion batteries pack a lot of energy into a small space, which is what makes them so good for powering phones and laptops, but it also means they can pose a fire risk if damaged, short-circuited, or exposed to heat.
We've all seen the exploding phone horror stories due to thermal runaway. Shipping regulations are designed to minimize these risks by limiting the size of batteries that can travel under simpler, less costly rules, alongside the UN38.3 altitude, vibration, and thermal tests that all lithium batteries must pass to prove they can be transported safely. By capping battery energy at 20Wh per cell for simplified transport, authorities reduce the chances of large-scale fires in trucks, ships, or aircraft cargo holds, which helps keep insurance costs down as well. Bigger batteries aren't banned outright, but they require more protective packaging, special documentation, and sometimes dedicated cargo handling to keep people and property safe.
Why do some phones still have 6,000mAh batteries?
Joe Maring / Android Authority
Did you spot the lawyer's way out of this conundrum? The 20Wh rule applies to single battery cells, but you can skirt this restriction if you pack two (or more) batteries together inside a gadget. Some smartphones have sported split-cell designs for more efficient fast charging for a number of years now, most noticeably from BBK brands OnePlus and OPPO. Hence, you'll still find a colossal 6,000mAh battery stateside with the OnePlus 13, and the OPPO Find X8 Pro makes its way to Europe with its 5,910mAh cell intact.
But that's not exactly a cheap solution; not only does it require multiple cells, but special circuitry to handle charging and discharging safely. Not every brand is willing to invest in that, which is one reason why Apple, Google, Samsung, and many others haven't pushed ahead with quite as large capacities as some of their Chinese competitors. Still, laptops have long used multiple smaller cells wired together to stay safely under the 100Wh pack limit, which is why we rarely see them run into shipping issues. Our smartphones will have to follow suit if we want to take another leap up in capacity.
More expensive split-cell designs are one way to boost phone battery life to new highs.
When it comes to phones manufactured and sold in China, the products move entirely internally, so many of the rules that govern international shipping don't apply or aren't enforced as strictly. Likewise, land transportation between China and its neighbours, along with localized manufacturing, helps explain why we occasionally see some larger capacity models make their way outside of China as well.
If you really want bigger batteries in your gadgets, we will either have to pay the premium for split cell designs, fork out for the cost, liability, and insurance premiums for shipping bigger batteries, or start manufacturing them locally. That latter point obviously isn't going to happen, so we might be snookered, which will unfortunately reduce the scale of the battery-life breakthroughs being made by technologies like silicon-carbon batteries.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a clinical collaboration to evaluate combinations of Revolution Medicines' investigational RAS(-ON) inhibitors with Summit Therapeutics' ivonescimab in multiple solid tumor settings. The collaboration will assess the safety and efficacy of these combinations in RAS mutant non-small cell lung cancer/NSCLC, pancreatic ductal adenocarcinoma/PDAC, and colorectal cancer/CRC. Under the agreement, Summit Therapeutics will supply ivonescimab for clinical research, while Revolution Medicines will serve as the study sponsor. Both companies will retain commercial rights to their respective compounds. A researcher poring over test results, illustrating the breakthrough potential of biotechnology. The agreement is mutually non-exclusive, allowing each company to pursue additional partnerships. Revolution Medicines will contribute 3 of its clinical-stage RAS(-ON) inhibitors to the collaboration: daraxonrasib (RMC-6236), which is a multi-selective inhibitor; zoldonrasib (RMC-9805), which is a G12D-selective inhibitor; and elironrasib (RMC-6291), which is a G12C-selective inhibitor. Revolution Medicines Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company. While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Associated Press
24 minutes ago
- Associated Press
DentScribe Launches GPS - AI-Powered "Guided Production System" Transforming Dental Practice Operations and Revenue Optimization
SAN JOSE, Calif., July 6, 2025 /PRNewswire/ -- today announced the launch of DentScribe GPS (Guided Production System), a groundbreaking addition to its AI-powered dental software suite, building upon the successful DentScribe CoPilot. DentScribe GPS provides dental practices with a comprehensive, practice-wide view of patient care, production opportunities, and actionable insights drawn directly from the dentist's AI-generated SOAP notes. Unlike traditional dashboards based on static diagnostic imaging (e.g., x-rays), DentScribe GPS leverages the dentist's own professional assessments captured in SOAP notes, reflecting the 'ground truth' of clinical needs and treatment plans. This real-time AI analysis ensures precise identification of high-value production opportunities, urgent patient care interventions, and daily operational priorities. DentScribe GPS delivers its insights through a user-friendly, tablet-first interface specifically optimized for morning huddles and daily planning sessions. Dental teams gain immediate visibility into critical alerts, planned production, patient follow-ups, and comprehensive practice performance metrics. DentScribe GPS visually categorizes opportunities by urgency, provider, discipline, and financial value, empowering teams to prioritize effectively. Dr. Vinni K. Singh, DDS, founder and CEO of remarked, 'DentScribe GPS changes everything about our morning huddles. We now start each day knowing exactly where to focus our efforts to maximize both patient care and practice profitability. By harnessing AI-driven insights directly from our SOAP notes, we are identifying care opportunities and revenue streams that diagnostic tools alone simply cannot see.' Early adopters report significant practice improvements, including: DentScribe GPS includes a unique Daily Brief (DentScribe GPS Intelligence), which provides a concise summary of critical daily priorities, revenue optimization strategies, and team productivity goals. Dental teams can quickly review key insights and make informed decisions at the start of each day. DentScribe GPS is now available nationwide, building upon the success of DentScribe CoPilot and further establishing DentScribe as the market leader in AI-driven dental practice management. To see DentScribe GPS in action and experience immediate, measurable results in your dental practice, schedule a demo today at Media Contact: [email protected] View original content to download multimedia: SOURCE DentScribe